Monthly information related to total number of voting rights and shares composing the share capital _July 31, 2023. Article 223-16 of general regulation of French Autorit© des March©s...
PRESS RELEASE PHAXIAM Therapeutics announces a reverse share split of its shares Reverse share split by the exchange of ten (10) existing shares with a par value of ten-euro cents (‚¬0.10) for one...
Phaxiam Therapeutics announces its new mnemonic code on Euronext and Nasdaq: PHXM Lyon (France) and Cambridge (MA, US), June 28, 2023 - Phaxiam Therapeutics (Nasdaq & Euronext: FR0011471135),...
ERYTECH and PHERECYDES announce merger and name change to PHAXIAM Therapeutics Merger approved with large majority by the shareholders of both companiesNew governance structure implementedAmbition to...
Erytech shareholders have sided with the company over a persistent activist investor, greenlighting a merger with Pherecydes months after the proposed deal was first announced.
ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder™s Meeting held on June 23, 2023 All resolutions voted with a large...
ERYTECH announces that Akkadian is continuing its attempt at destabilization with the filing of a new lawsuit Cambridge, MA (U.S.) and Lyon (France), June 20, 2023 “ ERYTECH Pharma (Euronext Paris...
ERYTECH announces that the Commercial Court has rejected Akkadian's request to postpone the vote on the merger with Pherecydes Pharma Cambridge, MA (U.S.) and Lyon (France), June 14, 2023, 8:00...
The war of words between Erytech and an activist investor trying to stall the long-planned merger with Pherecydes has reignited this week, with both sides firing off stinging press releases.
Monthly information related to total number of voting rights and shares composing the share capital _May 31, 2023. Article 223-16 of general regulation of French Autorit des...